News

Video

Personalized Cancer Vaccine Demonstrates Responses in Kidney Cancer

Fact checked by:

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.

Among patients with clear cell renal cell carcinoma, a form of kidney cancer, a personalized cancer vaccine demonstrated anti-cancer immune responses, according to recent study findings published in Nature.

The study enrolled nine patients with stage 3 and 4 clear cell renal cell carcinoma, who received a personalized cancer vaccine following the surgical removal of their tumors. The patients who received the vaccine experienced anti-cancer immune responses, with all patients remaining cancer-free at a median data cut-off of 34.7 months, or nearly three years, according to researchers.

CURE® spoke with the study’s co-senior author, Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston. In an interview, she noted that the current standard of care for this patient population is surgery.

“And then they wait,” she continued. “And 30% to 40% of those patients will relapse over time, within two years.”

Wu spoke with CURE about the unique aspects of clear cell renal cell carcinoma that make it a particularly challenging potential target for cancer vaccines.

Transcript:

Melanoma is so often a poster child for cancer immunotherapy. There are some unique aspects of melanoma, meaning that it's what we call a high mutation burden tumor. There are lots of different mutations to choose from. We kind of have an easier time creating a vaccine.

With renal cell [carcinoma], it's a much lower tumor mutation burden, so the bar is higher for us to work a little bit harder. One of the key things about the study is that we demonstrate that even with a lower-mutation burden tumor, we still are successful in consistently generating a vaccine for every patient that we treated; it can still generate a strong immune response

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Reference

“A neoantigen vaccine generates antitumour immunity in renal cell carcinoma” by Dr. David A. Braun et al., Nature.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Related Content